CD79B
Chr 17ARCD79b molecule
Also known as: AGM6, B29, IGB, Igbeta
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]
Primary Disease Associations & Inheritance
Agammaglobulinemia 6MIM #612692
AR
Clinical Summary— CD79B
🧬
Gene-Disease Validity (ClinGen)
agammaglobulinemia 6, autosomal recessive · ARDefinitive
Definitive — sufficient evidence for diagnostic panels
⚡
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.92). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
14 Pathogenic / Likely Pathogenic· 65 VUS of 206 total submissions
💊
Clinical Trials
2 active or recruiting trials — potential therapeutic options may be available
Some data sources returned errors (1)
ensembl: TimeoutError: The operation was aborted due to timeout
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.38LOEUF
pLI 0.916
Z-score 2.99
OE 0.08 (0.03–0.38)
More LoF-intolerant than ~75% of genes
Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
1.31Z-score
OE missense 0.68 (0.58–0.81)
93 obs / 136.1 exp
Mild missense constraint
Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.08 (0.03–0.38)
0≤0.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.68 (0.58–0.81)
0≤0.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.02
0≤1.21.6
LoF obs/exp: 1 / 12.4Missense obs/exp: 93 / 136.1Syn Z: -0.11
ClinVar Variant Classifications
206 submitted variants in ClinVar
Classification Summary
Pathogenic12
Likely Pathogenic2
VUS65
Likely Benign108
Benign15
Conflicting4
12
Pathogenic
2
Likely Pathogenic
65
VUS
108
Likely Benign
15
Benign
4
Conflicting
Curated Variants Distribution
Classified variants from ClinVar · 5 ACMG categories
| Classification | LoF | Missense + Inframe | Non-coding | Synonymous | Total |
|---|---|---|---|---|---|
Pathogenic | 0 | 1 | 11 | 0 | 12 |
Likely Pathogenic | 1 | 1 | 0 | 0 | 2 |
VUS | 0 | 55 | 9 | 1 | 65 |
Likely Benign | 1 | 1 | 49 | 57 | 108 |
Benign | 0 | 0 | 12 | 3 | 15 |
Conflicting | — | 4 | |||
| Total | 2 | 58 | 81 | 61 | 206 |
LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly
View in ClinVar →Protein Context — Lollipop Plot
CD79B · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
CD79B ANTIGEN; CD79B
MIM #147245 · *
Autosomal recessive
External Resources
Links to major genomics databases and tools
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R et al.·Signal Transduct Target Ther
2023
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD et al.·Nature
2018
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA et al.·Curr Treat Options Oncol
2018Review
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.
Phelan JD et al.·Cancer Cell
2024
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C et al.·Cancer Discov
2017Clinical trial
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC et al.·Lancet Oncol
2015Clinical trial
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.
Rawstron AC et al.·Cytometry B Clin Cytom
2018
Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Nieto-Jiménez C et al.·Clin Transl Med
2023Review
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas.
Kaimi Y et al.·Hematol Oncol
2026
CD79B in myelodysplastic syndromes and acute myeloid leukemia: an integrative computational and in vitro study.
Kong X et al.·Front Med (Lausanne)
2025Open Access
Combined transcriptome and function analyses of peripheral blood white cells highlight the disease-resistant mechanism of CD79a/CD79b in Chinese tongue sole (Cynoglossus semilaevis).
Tian M et al.·Fish Shellfish Immunol
2026Functional
MYD88 and CD79B Mutation Analysis in Primary Pharyngeal Diffuse Large B-Cell Lymphomas: Expanding the MCD-Like Subtype From the Sinonasal Region to the Upper Airway.
Peng F et al.·Pathol Int
2026
Gene Expression Profiling Provides an Improved Characterization of CD79B-Mutated Diffuse Large B-Cell Lymphomas.
Grossmann L et al.·J Pers Med
2025Open Access
Top 5 resultsSearch Europe PMC ↗
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
B-Cell Receptor Signaling and Beyond: The Role of Igalpha (CD79a)/Igbeta (CD79b) in Normal and Malignant B Cells
Tkachenko A et al.·Int J Mol Sci
2023
Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR
Zhong Y et al.·BMC Cancer
2024Cohort
Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma.
Kaimi Y et al.·Hum Pathol
2025
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies
Yadav R et al.·Pharmaceutics
2022
Human CD79b+ neutrophils in the blood are associated with early-stage melanoma
Meyer MA et al.·Front Immunol
2023
Zanubrutinib plus salvage chemotherapy in patients with refractory/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study
He S et al.·Ann Hematol
2025Cohort
Activation-induced cytidine deaminase causes recurrent splicing mutations in diffuse large B-cell lymphoma
Benitez-Cantos MS et al.·Mol Cancer
2024
A New Missense Mutation in CD79B Leads to Autosomal Recessive Agammaglobulinemia in Two Siblings.
Genebrier S et al.·J Clin Immunol
2021
Top 9 full-text resultsSearch PubTator3 ↗
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL
NOT YET RECRUITINGNCT07409428Phase PHASE3HutchmedStarted 2026-03-10
HMPL-760HMPL-760 PlaceboR-GemOx
HematologyDiffused Large B Cell Lymphoma
A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
NOT YET RECRUITINGNCT07065344AstraZenecaStarted 2025-08-31
External Resources
Links to major genomics databases and tools